The landscape of diabetes care is changing with the emergence of transdermal GLP-1 delivery . These novel patches offer a possibly more comfortable alternative to shots for individuals managing diabetes mellitus type 2 . These patches deliver a GLP-1 agonist directly through the dermis , avoiding the requirement for frequent injections and perhaps